Liu Lixing, Li Hao, Li Peijin, Zhou Rui, Zhang Qinglin, Liu Tingting, Feng Li
Department of Chinese Medicine, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
National Cancer Center, National Clinical Research Center for Cancer, Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, China.
Iran J Pharm Res. 2023 Apr 7;22(1):e134216. doi: 10.5812/ijpr-134216. eCollection 2023 Jan-Dec.
Malignant tumors are a significant disease endangering human health. Chinese Medicine (CM) plays an important role in comprehensive and holistic tumor treatment.
We aimed to investigate whether CM combined with the immunosuppressant PD-1/PD-L1 inhibitor has a good synergistic effect and can significantly improve response rates for the immunosuppressant.
We combined CM with immunosuppressant in treating six-week-old hepatocellular carcinoma-bearing mice and compared the outcomes of groups undergoing different interventions: blank group, control group, CM group, PD-L1 inhibitor group, and CM + PD-L1 inhibitor group, with ten mice in each group. The quality of life was evaluated along with the tumor inhibition effects and growth rates.
CM significantly reduced tumor load and improved the quality of life of cancer-bearing mice. The survival rate was 81.8% in the control group, 100% in the CM group, 90.9% in the PD-L1 inhibitor group, and 100% in the combined group in the first week. The survival rate was 45.5% in the control group, 54.5% in the CM group, 81.8% in the PD-L1 inhibitor group, and 81.8% in the combined group in the second week. 38% mice in the CM+PD-L1 inhibitor group with smaller tumor size than the average of the control group, which was much higher than other treatment groups. CM also reduced the expression of JAK2 mRNA and STAT3 mRNA, although not significantly (P > 0.05), and reduced PD-L1 mRNA in tumor tissue compared to the control group (P < 0.05).
CM had a synergistic effect on PD-L1 inhibitors and increased response rates to PD-L1 inhibitor treatment.
恶性肿瘤是危害人类健康的重大疾病。中医在肿瘤的综合整体治疗中发挥着重要作用。
我们旨在研究中医联合免疫抑制剂PD-1/PD-L1抑制剂是否具有良好的协同作用,并能显著提高免疫抑制剂的反应率。
我们将中医与免疫抑制剂联合用于治疗六周龄的荷肝癌小鼠,并比较不同干预组的结果:空白组、对照组、中医组、PD-L1抑制剂组和中医+PD-L1抑制剂组,每组10只小鼠。评估生活质量以及肿瘤抑制效果和生长速率。
中医显著降低了肿瘤负荷,改善了荷癌小鼠的生活质量。第一周,对照组的存活率为81.8%,中医组为100%,PD-L1抑制剂组为90.9%,联合组为100%。第二周,对照组的存活率为45.5%,中医组为54.5%,PD-L1抑制剂组为81.8%,联合组为81.8%。中医+PD-L1抑制剂组中38%的小鼠肿瘤大小小于对照组平均水平,这远高于其他治疗组。中医还降低了JAK2 mRNA和STAT3 mRNA的表达,尽管差异不显著(P>0.05),并且与对照组相比降低了肿瘤组织中PD-L1 mRNA的表达(P<0.05)。
中医对PD-L1抑制剂具有协同作用,并提高了对PD-L1抑制剂治疗的反应率。